NASDAQ:BGNE - BeiGene Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $334.88
  • Forecasted Upside: -2.15 %
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +9.71 (2.92%)

This chart shows the closing price for BGNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BeiGene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BGNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BGNE

Analyst Price Target is $334.88
▼ -2.15% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for BeiGene in the last 3 months. The average price target is $334.88, with a high forecast of $429.00 and a low forecast of $190.00. The average price target represents a -2.15% upside from the last price of $342.23.

This chart shows the closing price for BGNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in BeiGene. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$388.00 ➝ $417.00Low
6/3/2021Morgan StanleyBoost Price TargetOverweight$357.00 ➝ $409.00Low
5/10/2021Morgan StanleyLower Price TargetOverweight$375.00 ➝ $357.00Medium
3/16/2021HSBCBoost Price TargetBuy$296.00 ➝ $385.00Low
3/8/2021China Renaissance SecuritiesInitiated CoverageBuyLow
3/1/2021CLSADowngradeOutperform ➝ Underperform$330.00 ➝ $321.00Low
2/18/2021CowenBoost Price TargetOutperform$348.00 ➝ $429.00High
1/19/2021Morgan StanleyBoost Price TargetOverweight$310.00 ➝ $375.00Low
1/12/2021Piper SandlerBoost Price Target$185.00 ➝ $190.00High
12/8/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$278.00Low
11/19/2020SVB LeerinkBoost Price TargetOutperform$240.00 ➝ $327.00Medium
11/11/2020Morgan StanleyBoost Price TargetOverweight$270.00 ➝ $310.00Low
11/9/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
11/6/2020Maxim GroupDowngradeBuy ➝ HoldMedium
11/6/2020SVB LeerinkBoost Price TargetOutperform$210.00 ➝ $240.00High
11/6/2020Piper SandlerDowngradeNeutral ➝ Underweight$175.00 ➝ $185.00High
10/13/2020Morgan StanleyBoost Price TargetOverweight$241.00 ➝ $270.00High
8/10/2020Morgan StanleyBoost Price TargetOverweight$235.00 ➝ $241.00High
8/7/2020LADENBURG THALM/SH SHBoost Price TargetBuy$232.00 ➝ $268.00Medium
8/6/2020Piper SandlerBoost Price TargetNeutral$165.00 ➝ $175.00Medium
7/15/2020Morgan StanleyBoost Price TargetOverweight$190.00 ➝ $235.00Medium
7/10/2020Maxim GroupReiterated RatingPositive ➝ Buy$190.00 ➝ $250.00High
6/3/2020SVB LeerinkBoost Price TargetOutperform$207.00 ➝ $210.00Low
5/28/2020Morgan StanleyBoost Price TargetOverweight$184.00 ➝ $190.00Low
4/15/2020Morgan StanleyLower Price TargetOverweight$210.00 ➝ $184.00High
3/13/2020MacquarieUpgradeUnderperform ➝ NeutralHigh
3/3/2020Maxim GroupLower Price TargetPositive ➝ Buy$210.00 ➝ $190.00High
3/3/2020CowenReiterated RatingBuy$200.00High
2/18/2020The Goldman Sachs GroupInitiated CoverageBuy$197.30Low
1/27/2020CowenReiterated RatingOutperformMedium
1/17/2020Morgan StanleyInitiated CoverageOverweight$210.00Low
12/16/2019CowenReiterated RatingBuy$216.00Medium
12/16/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$165.00High
12/16/2019GuggenheimDowngradeBuy ➝ NeutralHigh
12/10/2019Maxim GroupReiterated RatingBuy$210.00Low
11/19/2019UBS GroupDowngradeBuy ➝ NeutralHigh
11/18/2019Bank of AmericaReiterated RatingBuy$230.00Low
11/15/2019Piper Jaffray CompaniesReiterated RatingBuy$200.00 ➝ $230.00High
11/15/2019GuggenheimReiterated RatingBuy$205.00 ➝ $228.00High
11/14/2019Maxim GroupReiterated RatingBuy$210.00Low
11/13/2019CowenBoost Price TargetOutperform$170.00 ➝ $225.00Low
11/4/2019JPMorgan Chase & Co.Set Price TargetBuy$162.00 ➝ $215.00Low
11/4/2019Maxim GroupBoost Price TargetBuy$170.00 ➝ $210.00Low
11/1/2019GuggenheimSet Price TargetBuy$205.00Low
11/1/2019Piper Jaffray CompaniesBoost Price Target$180.00 ➝ $200.00Low
10/16/2019CowenReiterated RatingBuy$170.00High
10/11/2019Morgan StanleyLower Price TargetOverweight$201.00 ➝ $200.00Low
8/12/2019Morgan StanleyLower Price TargetOverweight$207.00 ➝ $201.00Medium
8/9/2019Maxim GroupSet Price TargetBuy$170.00Low
7/15/2019Morgan StanleyLower Price TargetOverweight$210.00 ➝ $207.00Low
7/5/2019MacquarieInitiated CoverageUnderperformMedium
6/20/2019Piper Jaffray CompaniesReiterated RatingBuyLow
6/4/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Outperform$201.00Medium
5/31/2019Maxim GroupSet Price TargetBuy$170.00Low
5/31/2019CowenReiterated RatingBuy$170.00Low
5/14/2019Morgan StanleyBoost Price TargetOverweight$200.00 ➝ $210.00High
5/9/2019Piper Jaffray CompaniesBoost Price TargetPositive ➝ Overweight$180.00High
3/15/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$200.00Medium
2/28/2019Maxim GroupSet Price TargetBuy$170.00High
2/28/2019Piper Jaffray CompaniesLower Price TargetOverweight$170.00Low
1/3/2019Maxim GroupReiterated RatingBuy$170.00High
12/17/2018Maxim GroupReiterated RatingBuy$170.00Low
12/3/2018Maxim GroupSet Price TargetBuy$170.00High
12/2/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00High
11/28/2018JPMorgan Chase & Co.Initiated CoverageOverweight$174.00Medium
11/27/2018Maxim GroupSet Price TargetBuy$170.00Medium
11/20/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$174.00High
11/15/2018Maxim GroupSet Price TargetBuy$170.00Low
11/7/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00N/A
11/7/2018CowenReiterated RatingBuyMedium
10/14/2018CowenReiterated RatingBuyLow
9/24/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$215.00Medium
9/20/2018CowenReiterated RatingBuyLow
9/20/2018Maxim GroupReiterated RatingBuy$215.00Low
9/19/2018CLSAInitiated CoverageBuy$160.75Low
9/17/2018GuggenheimInitiated CoverageBuyLow
8/10/2018CowenReiterated RatingBuyLow
7/30/2018Maxim GroupReiterated RatingBuy$225.00Medium
7/23/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00Low
6/15/2018CowenReiterated RatingBuyLow
5/18/2018Maxim GroupBoost Price TargetBuy$200.00 ➝ $225.00Low
5/14/2018Credit Suisse GroupInitiated CoverageOutperform ➝ OutperformHigh
5/10/2018Maxim GroupSet Price TargetBuy$200.00High
4/16/2018Maxim GroupSet Price TargetBuy$200.00Low
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$200.00Medium
4/10/2018Maxim GroupBoost Price TargetBuy ➝ Buy$160.00 ➝ $200.00Low
3/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $200.00High
3/1/2018Robert W. BairdReiterated RatingHold$138.00High
3/1/2018LADENBURG THALM/SH SHReiterated RatingBuy$172.00Medium
3/1/2018Maxim GroupReiterated RatingBuy ➝ Buy$144.00 ➝ $160.00Medium
2/7/2018Maxim GroupReiterated RatingBuyLow
1/22/2018Maxim GroupSet Price TargetBuy$120.00Medium
1/8/2018CowenReiterated RatingBuyHigh
1/3/2018Maxim GroupSet Price TargetBuy$120.00Low
12/18/2017Maxim GroupSet Price TargetBuy$120.00Low
12/11/2017CowenReiterated RatingBuyLow
12/11/2017Maxim GroupSet Price TargetBuy$120.00Low
11/14/2017Maxim GroupSet Price TargetBuy$120.00N/A
11/14/2017CowenReiterated RatingBuyN/A
11/14/2017Robert W. BairdReiterated RatingOutperform ➝ Neutral$58.00 ➝ $83.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$87.00 ➝ $95.00N/A
9/28/2017Maxim GroupReiterated RatingBuy ➝ Buy$77.00 ➝ $120.00Low
9/11/2017Maxim GroupReiterated RatingBuy$77.00High
8/15/2017The Goldman Sachs GroupReiterated RatingBuy$43.00 ➝ $86.00Low
8/7/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$81.00High
7/10/2017Morgan StanleyReiterated RatingOverweight$83.00Medium
7/7/2017Maxim GroupBoost Price TargetBuy$57.00 ➝ $73.00High
7/6/2017Robert W. BairdBoost Price TargetOutperform$44.00 ➝ $58.00High
7/1/2017Maxim GroupSet Price TargetBuy$52.00 ➝ $57.00High
6/14/2017Maxim GroupSet Price TargetBuy$52.00Medium
6/5/2017Maxim GroupSet Price TargetBuy$52.00Low
6/1/2017William BlairReiterated RatingOutperformLow
5/11/2017Maxim GroupReiterated RatingBuy$52.00High
4/21/2017Maxim GroupSet Price TargetBuy$52.00Low
4/3/2017Maxim GroupSet Price TargetBuy$52.00Low
3/27/2017Maxim GroupReiterated RatingBuy$52.00Medium
3/11/2017Maxim GroupSet Price TargetBuy$52.00Low
3/2/2017Maxim GroupSet Price TargetBuy$52.00N/A
1/25/2017Maxim GroupSet Price TargetBuy$41.00N/A
12/5/2016Maxim GroupReiterated RatingBuyN/A
10/8/2016Maxim GroupSet Price TargetBuy$41.00N/A
10/7/2016CowenReiterated RatingBuyN/A
9/21/2016Maxim GroupInitiated CoverageBuy$41.00N/A
(Data available from 6/23/2016 forward)
BeiGene logo
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
Read More

Today's Range

Now: $342.23
Low: $334.99
High: $344.99

50 Day Range

MA: $331.18
Low: $292.75
High: $358.51

52 Week Range

Now: $342.23
Low: $181.17
High: $388.97


109,748 shs

Average Volume

249,929 shs

Market Capitalization

$31.49 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of BeiGene?

The following Wall Street sell-side analysts have issued reports on BeiGene in the last year: China Renaissance Securities Ltd., CLSA, Cowen Inc, HSBC Holdings plc, LADENBURG THALM/SH SH, Maxim Group, Morgan Stanley, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for BGNE.

What is the current price target for BeiGene?

8 Wall Street analysts have set twelve-month price targets for BeiGene in the last year. Their average twelve-month price target is $334.88, suggesting a possible downside of 2.1%. Cowen Inc has the highest price target set, predicting BGNE will reach $429.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $190.00 for BeiGene in the next year.
View the latest price targets for BGNE.

What is the current consensus analyst rating for BeiGene?

BeiGene currently has 2 sell ratings, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BGNE, but not buy more shares or sell existing shares.
View the latest ratings for BGNE.

What other companies compete with BeiGene?

How do I contact BeiGene's investor relations team?

BeiGene's physical mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company's listed phone number is 1-345-949-4123 and its investor relations email address is [email protected] The official website for BeiGene is